Key Segmentation
By Phage / Product Type
-
dsDNA Bacteriophage
-
ssDNA Bacteriophage
-
ssRNA Bacteriophage
-
Phage Cocktails / Engineered Preparations
-
Delivery / Formulation Types
By Administration / Route
-
Oral
-
Topical / External Application
-
Injectable / Surgical Administration
By Application / Use Case
-
Human Therapeutics
-
Veterinary Medicine
-
Agriculture & Crop Protection
-
Aquaculture
-
Food Safety & Preservation
-
Research & Development / Diagnostics
By End-User / Customer Type
-
Hospitals & Clinics
-
Pharmaceutical & Biotechnology Companies
-
Research & Academic Institutions
-
Veterinary Care Providers
-
Food & Beverage / Processing Industry
-
Agricultural Enterprises
By Target Bacterial Indication / Disease
-
Urinary Tract Infections
-
Wound & Skin Infections
-
Respiratory Infections
-
Bone & Orthopedic Infections
-
Chronic Conditions
-
Other Pathogen-Specific Indications
Request for Segment Customization as per your Business Requirement:
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: The Phage Therapy Market is projected to grow at a CAGR of 3.91% during 2026–2035.
Ans: The market is valued at USD 1.27 Billion in 2025 and is projected to reach USD 1.86 Billion by 2035.
Ans: Growth is driven by rising antibiotic resistance, wider adoption of phage therapies, advanced phage engineering, and expanding human, veterinary, and agricultural applications.
Ans: By Phage / Product Type, dsDNA Bacteriophage dominated with a 38.45% share, while Phage Cocktails / Engineered Preparations are projected to grow at the fastest CAGR of 5.42% during 2026–2035.
Ans: North America dominated with a 41.87% share in 2025, while Asia-Pacific is the fastest-growing region, projected to expand at a CAGR of 5.29% during 2026–2035.